Ivacaftor benzenesulfonateCFTR Potentiator CAS# 1134822-09-5 |
- BMS-509744
Catalog No.:BCC1424
CAS No.:439575-02-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1134822-09-5 | SDF | Download SDF |
PubChem ID | 78357768 | Appearance | Powder |
Formula | C30H34N2O6S | M.Wt | 550.67 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | VX-770 benzenesulfonate | ||
Solubility | 25℃: DMSO | ||
Chemical Name | benzenesulfonic acid;N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide | ||
SMILES | CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C.C1=CC=C(C=C1)S(=O)(=O)O | ||
Standard InChIKey | YLVYFBOFAFDIBR-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H28N2O3.C6H6O3S/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28;7-10(8,9)6-4-2-1-3-5-6/h7-13,27H,1-6H3,(H,25,28)(H,26,29);1-5H,(H,7,8,9) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Ivacaftor benzenesulfonate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.In Vitro:Ivacaftor (10 µM) increases the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants[1]. Ivacaftor (10 μM) significantly increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells[2]. Ivacaftor shows no significant activity against 160 targets tested including the GABAA benzodiazepine receptor. Ivacaftor increases the chloride secretion with an EC50 of 0.236 ± 0.200 μM, a 10-fold shift in potency compared to the F508del HBEs[3]. In recombinant cells, VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 increases forskolin-stimulated IT in temperature-corrected F508del-FRT cells by appr 6-fold with an EC50 of 25 nM[4].In Vivo:Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat[3]. References: |
Ivacaftor benzenesulfonate Dilution Calculator
Ivacaftor benzenesulfonate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.816 mL | 9.0798 mL | 18.1597 mL | 36.3194 mL | 45.3992 mL |
5 mM | 0.3632 mL | 1.816 mL | 3.6319 mL | 7.2639 mL | 9.0798 mL |
10 mM | 0.1816 mL | 0.908 mL | 1.816 mL | 3.6319 mL | 4.5399 mL |
50 mM | 0.0363 mL | 0.1816 mL | 0.3632 mL | 0.7264 mL | 0.908 mL |
100 mM | 0.0182 mL | 0.0908 mL | 0.1816 mL | 0.3632 mL | 0.454 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1] Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis. in vitro: In recombinant cells VX-770 increased CFTR channel open probability (P(o)) in both the F508del processing mutation and the G551D gating mutation. VX-770 also increased Cl(-) secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by approximately 10-fold, to approximately 50% of that observed in HBE isolated from individuals without CF [1]. in vivo: At day 28, in the group of subjects who received 150 mg of VX-770, the median change in the nasal potential difference (in response to the administration of a chloride-free isoproterenol solution) from baseline was -3.5 mV (range, -8.3 to 0.5; P=0.02 for the within-subject comparison, P=0.13 vs. placebo), and the median change in the level of sweat chloride was -59.5 mmol per liter (range, -66.0 to -19.0; P=0.008 within-subject, P=0.02 vs. placebo) [2]. Toxicity: Six severe adverse events occurred in two subjects (diffuse macular rash in one subject and five incidents of elevated blood and urine glucose levels in one subject with diabetes). All severe adverse events resolved without the discontinuation of VX-770 [2]. Clinical trial: Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CFTR Gating Mutation. Phase 3
- Ivacaftor hydrate
Catalog No.:BCC1664
CAS No.:1134822-07-3
- Epidanshenspiroketallactone
Catalog No.:BCN3142
CAS No.:113472-19-8
- Rhein-8-glucoside calcium salt
Catalog No.:BCN6349
CAS No.:113443-70-2
- VER 155008
Catalog No.:BCC2338
CAS No.:1134156-31-2
- Jatamanvaltrate B
Catalog No.:BCN7128
CAS No.:1134138-66-1
- 2-Aminophenyl phenyl sulfide
Catalog No.:BCC8553
CAS No.:1134-94-7
- Baclofen
Catalog No.:BCC8839
CAS No.:1134-47-0
- 2-Amino-4-phenylphenol
Catalog No.:BCC8534
CAS No.:1134-36-7
- γ-Truxilline
Catalog No.:BCN1948
CAS No.:113350-56-4
- neo-Truxilline
Catalog No.:BCN1949
CAS No.:113350-54-2
- GDC-0834
Catalog No.:BCC5115
CAS No.:1133432-50-4
- ABT-333
Catalog No.:BCC4129
CAS No.:1132935-63-7
- Ferulic acid
Catalog No.:BCN5948
CAS No.:1135-24-6
- Moxidectin
Catalog No.:BCC5309
CAS No.:113507-06-5
- Tracazolate hydrochloride
Catalog No.:BCC7115
CAS No.:1135210-68-2
- VU 0357017 hydrochloride
Catalog No.:BCC7907
CAS No.:1135242-13-5
- VU 0255035
Catalog No.:BCC7766
CAS No.:1135243-19-4
- SR 59230A hydrochloride
Catalog No.:BCC7094
CAS No.:1135278-41-9
- CGP 78608 hydrochloride
Catalog No.:BCC7087
CAS No.:1135278-54-4
- 3'-Fluorobenzylspiperone maleate
Catalog No.:BCC6752
CAS No.:1135278-61-3
- KN-92 phosphate
Catalog No.:BCC1682
CAS No.:1135280-28-2
- Altanserin hydrochloride
Catalog No.:BCC7183
CAS No.:1135280-78-2
- 6-Bnz-cAMP sodium salt
Catalog No.:BCC8043
CAS No.:1135306-29-4
- 25(S)-Hydroxyprotopanaxatriol
Catalog No.:BCN2495
CAS No.:113539-03-0